Moffitt Cancer Center to sponsor the Second Biennial Molecular Targets for Cancer Therapy Symposium

September 11, 2002

The H. Lee Moffitt Cancer Center & Research Institute will sponsor the Second Biennial Molecular Targets for Cancer Therapy symposium. This NCI-supported meeting is designed to foster the exchange of the most recent findings and concepts in cancer biology and to discuss how these ideas can be applied toward drug targets. Topics to be covered include gene regulation, signal transduction, immunology, apoptosis, and molecular therapeutics. The goal is to provide an in-depth view of these fast-moving fields so that information and advances in specific areas can be rapidly disseminated and applied to new problems. Special emphasis will be placed on bridging basic science and clinical research and creating new collaborations between disciplines.

The meeting will be held October 11-15, 2002 at the Don CeSar Beach Resort & Spa on St. Petersburg Beach, located 30 minutes from the H. Lee Moffitt Cancer Center at the University of South Florida in Tampa. The conference program will consist of a keynote address and 6 plenary sessions.

Conference Speakers:

Welcome Address:
William S. Dalton, Ph.D., M.D.
Center Director
H. Lee Moffitt Cancer Center & Research Institute

Keynote Address:
James E. Darnell, Jr., M.D.
Vincent Astor Professor and Head
Laboratory of Molecular Cell Biology
The Rockefeller University

Session I: Gene Regulation
Chair: C. David Allis, Ph.D
University of Virginia

Session II: Signal Transduction
Chair: Sara Courtneidge, Ph.D
Van Andel Research Institute

Session III: Immunology
Chair: Rainer Storb, M.D.
Fred Hutchinson Cancer Research Center

Session IV: Molecular Markers for Cancer Detection
Chair: Adi F. Gazdar, M.D.
University of Texas Southwestern Medical Center
Dallas, Texas

Session V: Apoptosis
Chair: Vishva Dixit, Ph.D
Genetech, Inc.

Session VI: Molecular Therapeutics
Chair: Stanton L. Gerson, M.D.
Case Western Reserve University and University Hospitals of Cleveland, Ohio

To view the Molecular Targets 2002 brochure in its entirety, go to www.moffitt.usf.edu/promotions/molecular/index.htm

Course Objectives
As a result of participating in this educational program, participants will be able to:
Accreditation For Physicians:
This activity has been planned and implemented in accordance with the Essentials Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of South Florida College of Medicine and H. Lee Moffitt Cancer Center and Research Institute. The University of South Florida College of Medicine is accredited by the ACCME to provide continuing medical education for physicians. The University of South Florida College of Medicine designates this educational activity for a maximum of 20.5 hours in category 1 credit towards the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Moffitt Cancer Center and Research Institute

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.